In the wake of its November 2016 decision to postpone release of final guidance on its possible regulation of laboratory-developed tests (LDTs), the FDA Jan. 13 posted online a discussion paper that attempted to synthesize stakeholder feedback on the draft guidance documents that the FDA had issued and offered what the agency called “a possible approach to LDT oversight.” Th... Read More